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Background. The Botswana antiretroviral program began in 2002 and currently treats 42,000 patients, with a goal of treating
85,000 by 2009. The World Health Organization (WHO) has begun to implement a surveillance system for detecting transmitted
resistance that exceeds a threshold of 5%. However, the WHO has not determined when this threshold will be reached. Here
we model the Botswana government’s treatment plan and predict, to 2009, the likely stochastic evolution of transmitted
resistance. Methods. We developed a model of the stochastic evolution of drug-resistant strains and formulated a birth-death
Master equation. We analyzed this equation to obtain an analytical solution of the probabilistic evolutionary trajectory for
transmitted resistance, and used treatment and demographic data from Botswana. We determined the temporal dynamics of
transmitted resistance as a function of: (i) the transmissibility (i.e., fitness) of the drug-resistant strains that may evolve and (ii)
the rate of acquired resistance. Results. Transmitted resistance in Botswana will be unlikely to exceed the WHO’s threshold by
2009 even if the rate of acquired resistance is high and the strains that evolve are half as fit as the wild-type strains. However,
we also found that transmission of drug-resistant strains in Botswana could increase to ,15% by 2009 if the drug-resistant
strains that evolve are as fit as the wild-type strains. Conclusions. Transmitted resistance will only be detected by the WHO
(by 2009) if the strains that evolve are extremely fit and acquired resistance is high. Initially after a treatment program is begun
a threshold lower than 5% should be used; and we advise that predictions should be made before setting a threshold. Our
results indicate that it may be several years before the WHO’s surveillance system is likely to detect transmitted resistance in
other resource-poor countries that have significantly less ambitious treatment programs than Botswana.
Citation: Vardavas R, Blower S (2007) The Emergence of HIV Transmitted Resistance in Botswana: ‘‘When Will the WHO Detection Threshold Be
Exceeded?’’. PLoS ONE 2(1): e152. doi:10.1371/journal.pone.0000152
INTRODUCTION
Antiretroviral therapy (ART) has drastically reduced mortality and
morbidity of HIV/AIDS in resource-rich countries; however there
are now fairly high levels of drug resistance in many of these
countries [1]. Therefore there is concern that the rollout of ART
in Africa could quickly lead to high levels of transmitted resistance
arising which would reduce the effectiveness of epidemic control
efforts. The World Health Organization (WHO) has developed
a surveillance system for monitoring the emergence of transmitted
resistance in resource-poor countries [2,3]. The WHO detection
methodology is based upon a binomial sequential lot quality
assurance (BSLQA) sampling method with an arbitrary detection
threshold of 5% [4,5]. This threshold enables determination of
whether the incidence of transmitted resistance lies in one of three
categories: less than 5%, 5% to 15% or over 15%. The range of
the minimal number of newly infected treatment-naı ¨ve adults that
need to be sampled to detect a 5% threshold ranges from 50 to 70
newly infected treatment-naı ¨ve adults [2,3]. Hence the BSLQA
methodology is cost-effective and easy to implement, but will not
be able to detect transmitted resistance until it has exceeded 5% of
the incidence rate. It is unknown when the 5% threshold will be
reached in any country, because the WHO has not made any
country-specific predictions to determine how quickly transmitted
resistance is likely to evolve. Here we develop a mathematical
model that can be used to make short-term predictions for the
emergence and stochastic evolution of transmitted resistance in
a resource-poor country. We use our model to determine when the
WHO’s 5% threshold is likely to be exceeded in Botswana.
Botswana is one of the world’s worst hit countries by the AIDS
pandemic. An estimated 39% of Botswana’s 730,000 adults
between the ages of 15 and 49 are HIV-infected [6]. In 2002
HIV/AIDS was declared the most serious threat to the country,
and their ART program was initiated. Currently the program
treats 42,000 patients [7]. The goal is to treat 85,000 patients (or
equivalently 30% of their HIV-infected individuals) by 2009 [8].
Botswana has by far the highest treatment rate in Africa, and has
already slightly exceeded their scheduled annual treatment targets.
Botswana is now considered a test nation by foreign investors for
ART programs in sub-Saharan Africa. Recent substantial financial
investments have enabled the opening of 31 treatment centers,
ensuring that Botswana is quite likely to reach the government
treatment goal by 2009. We use our stochastic model to predict the
expected magnitude, and the temporal dynamics, of transmitted
resistance in Botswana by modeling their government treatment
plan. Specifically, we predict the likely evolutionary trajectory of
transmitted resistance (due to the Botswana government’s
treatment plan) by varying: (i) the rate of acquired resistance,
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We conclude by discussing the implications of our results in the
context of the WHO’s surveillance system for transmitted resistance.
The first-line drug regimen used in Botswana is a fixed
combination of Zidovudine, Lamivudine, and Nevirapine or
Efavirenz [9]. The evolution of transmitted resistance is driven
by three key parameters: the treatment rate, the rate of
development of acquired resistance and the fitness of the drug-
resistant strains that evolve [1,10]. We modeled the specific
treatment rate for Botswana (see Materials & Methods and
Mathematical Details S1 section 1). Thus, we investigated
the effect of the other two key parameters on the evolution of
transmitted resistance in Botswana. The rate of acquired resistance
depends upon adherence, viral replication rate, and the specific
mutations that arise [1]. Acquisition of one mutation will not
necessarily reduce the clinical efficacy of a regimen; thus we did
not model the accumulation of mutations, we modeled the
virological failure rate due to acquired resistance. Under perfect
adherence, only 5–10% of patients are likely to develop drug
resistance in the first year [11]. However, if adherence is less than
100%, a greater proportion of patients will develop drug resistance
within a year [12]. Recent studies on adherence in sub-Saharan
Africa indicate that very favorable adherence rates can be reached
and that these adherence rates can often be higher than those
reported from North America: 77% adherence rates in Africa
compared to 55% adherence rates in North America [13].
However patients in Botswana may suffer from poor treatment
accessibility and interruption of drug supply which could
compromise their adherence to treatment [14]; hence it is possible
that rates of acquired resistance in Botswana could be high. In
order to make worst case predictions, and to maximize the speed
at which transmitted resistance could arise, we modeled high rates
of acquired resistance. To make our short-term predictions we
assumed that (on average) either 20% or 33% of treated patients
could develop acquired resistance per year [15–19]. By consider-
ing the worst case scenarios for the rates of acquiring resistance we
were able to determine the earliest times that transmitted
resistance could reach the 5% detection threshold.
Patients who acquire resistance have the potential to transmit
resistant strains via sexual transmission. Relatively little is known
about the fitness of resistant strains of HIV in vivo. However, in vitro
experiments have shown that the replication rates of resistant
strains are generally less than that of wild-type strains [20–22].
Thus, it has often been assumed that resistant strains will always be
less transmissible than wild-type strains. However, certain
mutations may substantially reduce fitness whereas other muta-
tions may have little effect. Hence it is possible that some drug-
resistant strains could be almost as transmissible as wild-type
strains. To consider all possibilities we examined the potential
impact on transmitted resistance of a wide variety of mutations by
varying the fitness of drug-resistant strains relative to wild-type
strains from 0% to 75%. Specifically, we modeled the potential
impact on transmitted resistance of drug-resistant strains with
a relative fitness of: (i) 100%, (ii) 50%, or (iii) 25% [23]. The
parameter values of the transmissibility/fitness of the wild-type
strains and of the drug-resistant strains were calculated based upon
the viral load of the treatment regimen (i.e., Zidovudine,
Lamivudine, and Nevirapine or Efavirenz [9]) that is used in
Botswana (see Mathematical Details S1 section 1.2 for
further discussion of calculation of these parameters). It should be
noted that resistant strains that have low fitness may acquire
compensatory mutations and hence increase their fitness over the
long-term. Since our predictions are only short-term (i.e., only to
2009) we ignored the evolution of fitness.
There are relatively few mathematical models of ART and drug
resistance; notably the first was in 2000 by Blower et al.[24]. Since
then other studies have presented similar models [25,26]. All three
of these models have been based on deterministic formulations of
the dynamics of HIV resistance. However, the early stages of the
dynamics of an ART program are subject to large variability and
therefore necessitate a stochastic treatment. In the analysis
presented in this manuscript we are the first to develop a stochastic
model of the evolution of drug resistance. We made projections for
transmitted resistance in Botswana by first formulating a continu-
ous-time Markov chain model; see Materials & Methods for
mathematical details. To construct this model we developed
a combination of deterministic and stochastic equations (see
Mathematical Details S1 sections 1 & 2 for detailed
description and discussion). Deterministic equations were used to
predict the dynamics of the number of adults in Botswana who are:
(i) susceptible or (ii) infected with wild-type strains of HIV and
treatment-naı ¨ve or(iii) infected with wild-typestrainsofHIVandon
treatment. Their values are relatively large and currently are
approximately 460,000 and 280,000 and 34,000 respectively. Thus,
relative stochastic fluctuations in these three groups could be
neglected and the mean-field dynamics from the deterministic
version of our stochastic model used. However ART has only been
available in Botswana since 2002 therefore the number of adults
infectedwithdrug-resistantstrainsisrelativelysmallandquantifying
the stochastic fluctuations in transmitted incidence is important.
Essentially we are predicting the initial stage of an epidemic;
specifically, the early stage of a drug-resistant HIV epidemic. At this
early stage the population dynamics of transmitted resistance will be
subject to a high degree of random (i.e., stochastic) fluctuations
1.
Capturing the effect of these stochastic fluctuations is an important
part of any predictions made of the early stages of an epidemic.
Therefore, in addition to mean-field predictions of transmitted
resistance we also predicted the dynamics of the variance and
skewness of these stochastic fluctuations by formulating and using
a stochastic dynamic version of the deterministic model (see
Mathematical Details S1 section 2.1). We derived a birth-
death-immigration Master equation from our stochastic dynamic
model, solved the Master equation analytically and used this
analytical solution to determine explicit expressions for the mean,
variance and skewness of the evolutionary dynamics [27–29] (see
Mathematical Details S1 section 2.3). We then used these
explicit expressions to predict the stochastic evolutionary trajectory,
to 2009, of transmitted drug-resistant strains in Botswana. This
approach is valid over the short-term dynamics. We chose not to
simulatethe processnumericallyvia MonteCarlosimulationsasour
aim was to obtain expressions from which one can directly obtain
the magnitude of the fluctuation [30].
RESULTS
We constructed the stochastic model by first formulating a de-
terministic version of the model and determining the mean-field
dynamics. We then developed a stochastic version of the
deterministic model and obtained the Master equation of the
processes (see equation 1):
LPk(t)=Lt~rYT
S (t)½Pk{1(t){Pk(t) zbRcX(t)=N(t)
½(k{1)Pk{1(t){kPk(t) {(vRzm)½kPk(t){(kz1)Pkz1(t) ,
ð1Þ
1It is the relative fluctuations that are large during the early stages of the
epidemic. Indeed, the cumulative random fluctuations increase with time.
However, these become progressively less important as a fraction of the
prevalence. Therefore, as a fraction of the prevalence, random fluctuations are
mostly important during the early stages of an epidemic.
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of drug-resistant HIV is k. The Master equation consists of three
terms: the first term represents the process by which individuals
acquire resistance; the second term represents the process whereby
individuals transmit drug-resistant strains and the last term
represents the process whereby individuals develop AIDS or die
in the process of developing AIDS. This Master equation was
reformulated in terms of a cumulant generating function. By
solving the latter equation we obtained a solution that provided
the time dynamics of the central moments of the probability
distribution Pk(t). We retained the first three central moments, and
therefore obtained the dynamics of the mean, variance and
skewness of the prevalence of transmitted resistance. Finally, we
used this solution to obtain the generating function of the
incidence and therefore also obtained the dynamics of the mean,
variance and skewness of the incidence of transmitted resistance
(see Mathematical Details S1 section 2.4). We used these
solutions to generate our projections of the likely evolutionary
trajectory of transmitted resistance that is to be expected as a result
of the Botswana governments’ treatment plan.
In order to solve the Master Equation we had to make the
approximation that the proportion of the adults that were
uninfected remained constant throughout the time frame of our
predictions. To test this approximation we compared the mean-
field predictions obtained by solving the Master equation to those
obtained by the numerical integration of the deterministic version
of the model for the duration of interest (i.e., up to 2009). We
found that the percentage error made by the mean-field solution of
the Master equation was only 6% in absolute values by 2009; this
6% error translates into an overestimation (during the last quarter
of 2008) of the cumulative incidence of transmitted resistance by
,74 individuals out of a total number of 1230
2.
By using the generating function for cumulative incidence over
periods of 3 months we determined that whether the WHO
surveillance threshold of 5% is likely to be exceeded by 2009
depends critically upon both the fitness of the drug-resistant strains
and the rate of development of acquired resistance. Data shown in
Fig. 1 are predictions obtained by using the analytical expression
for the mean transmitted incidence of the drug-resistant strains
and are expressed as a fraction of the total incidence for both wild-
type and drug-resistant strains (see Mathematical Details S1
section 2.3 & 2.4). The vertical bars show the corresponding
expected probabilistic fluctuation ranges, within one standard
deviation, due to the stochasticity in the dynamics. These
probabilistic ranges were obtained using both the expressions for
the variance and skewness in the cumulative incidence over 3
month periods (see Mathematical Details S1 section 2.4).
Panels (1A), (1C) and (1E) show probabilistic predictions when we
assumed that (on average) 20% of the patients would acquire drug
resistance per year (i.e., that on average all of the patients would
develop resistance in 5 years). Panels (1B), (1D) and (1F) show
probabilistic predictions when we assumed that 33% of the
patients would acquire drug resistance per year (i.e., that, on
average, all of the patients would develop resistance in 3 years).
The relative fitness of the drug-resistant strains with respect to the
wild-type strains that are used in the calculations are: (i) 25%
(Fig. 1A) and (Fig. 1B), (ii) 50% (Fig. 1C) and (Fig. 1D), and (iii)
100% (Fig. 1E) and (Fig. 1F).
Our results show that if the drug-resistant strains that evolve are
only 25% as fit as the wild-type strains then transmitted resistance
will reach only ,3% in the next three years (Fig. 1A). Thus the
WHO surveillance threshold is not likely to be exceeded by 2009,
even if the rate of acquired resistance is very high (Fig. 1B).
Transmitted resistance will reach 6% by 2009 if the drug-resistant
strains that evolve are half as fit as the wild-type strains and the
rate of acquired resistance is very high (Fig. 1D). Thus, under these
conditions, the WHO surveillance threshold is likely to be
exceeded. If the drug-resistant strains that evolve are half as fit
as the wild-type strains, but the rate of development of acquired
resistance is only 20% per year, transmitted resistance will only
rise to just below 5% by 2009 (Fig. 1C). Hence, under these
conditions, the WHO surveillance threshold may not be exceeded.
The expected probabilistic fluctuations are large enough that there
is a fair probability that transmitted drug resistance could rise to
just above 5% by 2009, and thus exceed the threshold. Finally, if
the drug-resistant strains that emerge are as fit as wild-type strains
then the threshold will be reached in 2006 (Fig. 1F) or 2007
(Fig. 1E), and levels of transmitted resistance could be as high as
13% by 2009 (Fig. 1F). Obviously, if drug-resistant strains evolve
that are more fit than wild-type strains the levels of transmitted
resistance will be even higher by 2009 (results not shown). It is also
possible that transmitted resistance may not be observed at all if
a more suppressive treatment regimen is used than is currently
planned.
DISCUSSION
We have used a fairly simple stochastic model to predict, to 2009,
the evolutionary trajectory for the incidence of transmitted resist-
ance that is to be expected to occur in Botswana as a result of the
government’s treatment plan. Our model includes the principle
processes that are involved in the short-term dynamics of the
emergence of drug resistance in a sub-Saharan African country
once a treatment plan has been initiated. It has sometimes been
argued, on the basis of a high viral load, that primary infection
maybe responsible for a large percentage of infections [31].
However, the length of time spent in the primary infection stage is
substantially shorter (i.e., only a couple of months) than the length
of time that is spent in the later stages of HIV infection which is
generally many years before developing AIDS. Consequently, due
to the differential length of time in these stages, the number of
individuals that are in the primary infection stage at any one time
are substantially fewer than the number of individuals that are in
the later (but still untreated) stages of HIV infection. Consequently
we did not deem it necessary to model explicitly the effect of
primary infection as we were making only short-term predictions.
A more detailed model that includes additional processes such as
reversion of drug-resistant strains, the effects of super-infection and
primary infection should be developed if longer-term predictions
are to be made. However, it should be noted that for short-term
predictions the contribution of such processes has fairly minimal
effects. Generally, all processes that have time scales much larger
than the time frame chosen for making short-term predictions can
be safely ignored. Nor, did we include the process of vertical
transmission of drug resistance. Our model captures only the
dynamics of transmitted resistance that have occurred due to
sexual transmission, because this is the type of transmitted
resistance that will be monitored in Botswana by the WHO’s
surveillance system.
It is possible that HIV infected individuals will obtain ART
outside the official treatment program. This could potentially
increase levels of transmitted resistance. Since Botswana plans to
treat, by 2009, a very high percentage (,30%) of HIV infected
individuals the number of HIV-infected individuals who will need
to obtain drugs outside the program is likely to be fairly small.
2This number was obtained by considering the worst case scenario using the
highest rate of both acquired resistance and transmitted resistance that we have
considered.
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uals is likely to make only a small contribution to the incidence
rate. We stress that the analytical expressions that we have
formulated are only valid for short-term dynamics (i.e., a few
years) when the proportion of the population that is uninfected
and the proportion that is infected with wild-type and treatment-
naı ¨ve stay approximately at their equilibrium values. The
approximation of equilibrium is appropriate for Botswana over
the next few years because: (i) the population infected with wild-
type HIV and treatment-naı ¨ve is very large, currently approxi-
mately 280,000 adults, and (ii) and prevalence is approximately
stable at 40% (the prevalence is stable as the death rate plus the
rate of adults that develop AIDS for in Botswana has reached
a high level and approximately balances the incidence rate). Use of
our analytical expressions beyond short-term dynamics would be
inappropriate because of the assumptions that have been made.
Furthermore, in the regime beyond short-term dynamics,
stochastic effects are increasingly less important and therefore
often stochastic models are unnecessary to predict long-term
dynamics.
Botswana will have achieved high treatment rates by 2009. Our
results imply that, unless the drug-resistant strains that evolve in
Botswana are extremely transmissible, the WHO threshold for
detection of transmitted resistance is unlikely to be exceeded by
2009. Although the BSLQA method using a threshold value of 5%
requires a small sample size and is relatively inexpensive it may
actually not be cost-effective at the early stages of the treatment
program. Therefore, it may be appropriate to consider using
Figure 1. Predictions using the cumulant generating function showing quarter yearly expected percentage values of transmitted resistance due to
the Botswana’s government treatment plan. The vertical bars represent the possible range of values due to the stochastic fluctuation contained in
one standard deviation over the expected percentage. Here, we have assumed that the average progression time to AIDS for HIV infected patients
that are treatment-naı ¨ve, treated drug-sensitive and drug-resistant are 10, 18 and 12 years respectively [23,33]; however since our predictions are only
for three years our results are robust with respect to this assumption. The untreated and treated drug-sensitive transmissibility coefficient per
partnership were calculated, on the basis of the Botswana treatment regimen of a fixed combination of Zidovudine, Lamivudine, and Nevirapine or
Efavirenz, to be 0.12 and 0.04 respectively [31,34,35] (see Mathematical Details S1 section 1.2 to see how the values of these parameter estimates
were derived). The patient population has an average annual probability of developing drug resistance specified by the parameter r, and the
transmissibility/fitness of drug-resistant strains is specified by the parameter bR (see Mathematical Details S1 section 1.2 to see how the values of
these parameter estimates were derived). The six panels show predictions using the following parameter sets: (A) r
21=5 years, bR=0.03 (B) r
21=3
years, bR=0.03 (C) r
21=5 years, bR=0.06 (D) r
21=3 year, bR=0.06 (E) r
21=5 years, bR=0.12 (F) r
21=3 years, bR=0.12.
doi:10.1371/journal.pone.0000152.g001
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transmitted resistance dynamics. Our predictions show that
checking for transmitted resistance in Botswana in early 2007
using a lower threshold value of ,3% would provide a more
accurate representation of the present situation. If transmitted
resistance is found to be at or above 3% then repeating the
BSLQA test in the next scheduled occasion using a 5% threshold
value would provide more information as to how quickly
transmitted resistance is increasing in Botswana. Although this
would be more expensive, it would probably be more cost-effective
than the current strategy.
We stress that other models should be constructed and their
results compared with our predictions. We propose that the
WHO’s surveillance system should be designed on the basis of
quantitative predictions and should not be based upon specifica-
tion of arbitrary thresholds. We advise that, at the beginning of
treatment programs in resource-poor countries, that the detection
threshold should be lower than 5% in order to detect transmitted
resistance. A lower threshold would require a larger sample size
and therefore would be more expensive, although potentially more
effective. We recommend that WHO surveillance should be
initiated in Botswana, and in resource-poor countries, only when
transmitted resistance is expected to exceed the threshold.
However, sentinel sites for surveillance should be used throughout
the rollout [1]. We also suggest that quantitative predictions for
transmitted resistance should be made for other countries where the
rollout of ART is just beginning. We conclude that it is likely that, if
the 5% threshold is used, it could be many years before the WHO
will detect transmitted resistance in other resource-poor countries
that have less ambitious treatment programs than Botswana.
MATERIALS AND METHODS
To predict the stochastic evolution of transmitted resistance we
developed a continuous time Markov chain model; see Mathe-
matical Details S1, a flow diagram and the model equations for
both the deterministic (section 1.1) and stochastic version of the
model (section 2). The Mathematical Details S1 also includes
parameter definitions and estimations (section 1.2), initial
conditions (section 1.3) and a comparison between the de-
terministic and the stochastic model (section 2.5).
We modeled the stochastic dynamics of the emergence (by
acquired resistance) and the evolutionary trajectory of transmitted
resistance after the introduction of ART at the beginning of the
Botswana treatment program to 2009. Our stochastic Markov
chain model captures the essential processes of HIV transmission
dynamics (see Mathematical Details S1 for details of
mathematical structure). Each year a proportion of the drug-naı ¨ve
HIV-infected group initiates treatment, a proportion of the treated
group discontinues treatment, and a proportion of the treated
group develops acquired resistance [32]. We calculated the
treatment rate from the projected number of patients that the
Botswana ART program plans to treat over the next three years.
The program plans to treat 85,000 patients by 2009 [8] (Figure 2).
The treatment rate was found by assuming that it remains
constant such that by the year 2009 Botswana will have 85,000
patients that have received ART; this is the planned treatment
goal of the Botswana government. Our modeled treatment rate
(dashed gray line) and the actual data from 2002 to 2005 (dashed
red line) are extremely close and are shown in Figure 2. Treatment
benefits were modeled, in treated patients in comparison with
untreated HIV-infected individuals, by increasing life expectancy
(1/vS
T.1/vS
U) [12] (see Mathematical Details S1 section 1.2
for parameter definitions) and by reducing viral load (and hence
transmissibility/fitness: bS
U.bS
T). The patient group has an
average annual probability of developing drug resistance specified
by the parameter r. Treated individuals that develop drug
resistance increase their viral load and progress to AIDS faster
than treated individuals infected with wild-type strains (1/vS
T.1/
vR); however it should be noted that since our predictions are only
for three years our results are robust with respect to this
assumption. Individuals infected with drug-resistant strains can
transmit these strains; the transmissibility/fitness of drug-resistant
strains is specified by bR (see Mathematical Details S1 section
1.2 for how this parameter was calculated).
Figure 2. Empirical data from the Botswana’s government treatment program are shown by the filled boxes. The aim of the Botswana ART program is
to reach 85,000 patients by 2009 (black dashed line) [8]. The treatment used by our model uses the linear fit shown by the dashed gray line, this gives
a constant per capita treatment rate of 0.050 per year.
doi:10.1371/journal.pone.0000152.g002
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Mathematical Details S1 Here we present technical details
that describe mathematical methodologies and analytical deriva-
tions used for our results presented in the main text and parameter
estimates. In section 1 we present our mathematical model, which
describes the dynamics of the emergence of acquired and
transmitted drug-resistant HIV in a population. This is followed
by a discussion of the parameters used in the model. We formulate
the ordinary differential equations (ODEs) describing the mean-
field population dynamics and describe the initial conditions for
the model. In section 2 we formulate the dynamics of the drug-
resistant population using a Markov chain equation and we discuss
the approximations required for this formulation to produce
acceptably accurate dynamics. We then show how this can be used
to obtain expressions for the evolution of the mean, variance and
skewness of the cumulative transmitted resistance.
Found at: doi:10.1371/journal.pone.0000152.s001 (0.17 MB PDF)
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